Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Scagliotti, G. et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14, 253–263 (2009).
2. Johnson, D. H. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184–2191 (2004).
3. Vanderbilt-Ingram Cancer Center. My Cancer Genome,
https://www.mycancergenome.org/
(2018).
4. Lindeman, N. I. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J. Thorac. Oncol. 13, 323–358 (2018).
5. Travis, W. D. et al. (eds) WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 1–412 (IARC Press, Lyon, France, 2015).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献